268 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Why Gilead Sciences Might Not Make an Oncology Acquisition https://www.fool.com/investing/2017/08/15/why-gilead-sciences-might-not-make-an-oncology-acq.aspx?source=iedfolrf0000001 Aug 15, 2017 - Gilead Sciences' CEO hints that buying a biotech with an oncology focus might not happen. Here's what this could mean for the big biotech.
3 Beaten-Up Biotech Stocks: Are They Bargains? https://www.fool.com/investing/2017/08/14/3-beaten-up-biotech-stocks-are-they-bargains.aspx?source=iedfolrf0000001 Aug 14, 2017 - It's been a pretty good year for biotech, but these three stocks have tumbled. Is the pessimism overblown?
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions? https://www.fool.com/investing/2017/08/13/why-has-2017-been-a-horrible-year-so-far-for-biote.aspx?source=iedfolrf0000001 Aug 13, 2017 - Big biotech deals have been few and far between so far in 2017. But just wait till next year.
Incyte (INCY) Q2 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4093287-incyte-incy-q2-2017-results-earnings-call-transcript?source=feed_all_articles Aug 01, 2017 - Incyte Corp. (NASDAQ:INCY)Q2 2017 Earnings CallAugust 01, 2017 10:00 am ETExecutivesMichael Charles A. Booth - Incyte Corp.Hervé Hoppenot - Incyte Corp.Barry P. Flannelly - Incyte Corp.Steven H. Stein
2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't https://www.fool.com/investing/2017/07/21/2-reasons-incyte-is-a-better-growth-stock-than-exe.aspx?source=iedfolrf0000001 Jul 21, 2017 - Which is the better growth stock going forward -- Exelixis or Incyte? It depends.
3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now? https://www.fool.com/investing/2017/07/20/3-hottest-biotech-stocks-of-2017-are-they-still-bu.aspx?source=iedfolrf0000001 Jul 21, 2017 - Calthera Biosciences, Aurinia Pharmaceuticals, and Esperion Therapeutics are some of the hottest biotech stocks in 2017, and catalysts that are on deck could suggest there's more upside ahead.
3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months https://www.fool.com/investing/2017/07/15/3-stocks-that-turned-1000-into-at-least-2017-in-12.aspx?source=iedfolrf0000001 Jul 15, 2017 - You don't need a million bucks to have a winning portfolio.
Better Buy: Agenus Inc. vs. Kite Pharma https://www.fool.com/investing/2017/07/02/better-buy-agenus-inc-vs-kite-pharma.aspx?source=iedfolrf0000001 Jul 02, 2017 - Is Agenus or Kite Pharma the better oncology stock to own right now?
Aduro Starts Phase II Combo Study with CRS-207 & Keytruda http://www.zacks.com/stock/news/266022/aduro-starts-phase-ii-combo-study-with-crs-207-keytruda?cid=CS-ZC-FT-266022 Jun 29, 2017 - Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).
A Surprising Disappointment Derails NewLink Genetics -- What's Next? https://www.fool.com/investing/2017/06/19/a-surprising-disappointment-derails-newlink-geneti.aspx?source=iedfolrf0000001 Jun 19, 2017 - Roche Holdings has decided to walk away from co-developing NewLink Genetics IDO-inhibitor, GDC-0919.
<<<Page 21>